Adria Myers has no relevant financial relationships to disclose. Holly Chitwood has participated in oncology nurse education advisory boards with Gilead Sciences, Astra Zeneca, and in biomarker database peer review for the Oncology Nursing Society.
Define circulating tumor DNA (ctDNA) and appraise evolving technology
Describe current ctDNA application with solid tumors and emerging indications in practice with an overview of commercially available assays
Discuss the advanced practice provider's role in ctDNA utilization
Identify emerging clinical trial data and evolving recommendations for ctDNA utilization